With 0.73 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.74 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $26.8 whereas the lowest price it dropped to was $25.495. The 52-week range on NAMS shows that it touched its highest point at $27.29 and its lowest point at $11.18 during that stretch. It currently has a 1-year price target of $43.44. Beta for the stock currently stands at -0.03.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NAMS was up-trending over the past week, with a rise of 0.04%, but this was up by 32.18% over a month. Three-month performance surged to 48.94% while six-month performance rose 29.80%. The stock gained 117.24% in the past year, while it has gained 1.01% so far this year. For the next quarter, that number is -0.49. This implies an EPS growth rate of 5.04% for this year and 10.30% for next year.
Float and Shares Shorts:
At present, 92.17 million NAMS shares are outstanding with a float of 50.45 million shares on hand for trading. On 2024-12-13, short shares totaled 2.58 million, which was 241.0 higher than short shares on 1731628800. In addition to Dr. Michael Harvey Davidson FACC, Facp., M.D. as the firm’s CEO, President, Executive Board Member & Director, Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. serves as its Founder, Chief Scientific Officer, Member of Executive Board & Director.
Institutional Ownership:
Through their ownership of 0.79928 of NAMS’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, NAMS reported revenue of $29111000.0 and operating income of -$23868000.0. It generated -$16647000.0 net income for the quarter, which came to $35.40M over the last twelve months. The EBITDA in the recently reported quarter was -$27752000.0 and diluted EPS was -$0.18. EBITDA for the full year was $33.80M.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NAMS since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With NAMS analysts setting a high price target of 50.445 and a low target of 27.954, the average target price over the next 12 months is 41.62178. Based on these targets, NAMS could surge 94.32% to reach the target high and rise by 7.68% to reach the target low. Reaching the average price target will result in a growth of 60.33% from current levels.
Analysts have provided yearly estimates in a range of -$1.73733 being high and -$2.05234 being low. For NAMS, this leads to a yearly average estimate of -$1.96643.
